Dupixent® Injections and Cutaneous T-Cell Lymphoma Law Firm
Dupixent® Injections and Cutaneous T-Cell Lymphoma Law Firm
Ward & Ward Personal Injury Lawyers, are accepting clients who have received a skin cancer diagnosis of Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent® injections for at least one month or longer.
- Dupixent® injections and Cutaneous T-Cell Lymphoma Law Firm, Ward & Ward Personal Injury Lawyers, are accepting clients who have received a skin cancer diagnosis, specifically Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent® injections.
- The manufacturers of Dupixent® failed to warn the public of the unseen risk of developing a very rare skin cancer known as Cutaneous T-Cell Lymphoma—or the worsening of an existing skin Cutaneous T-Cell Lymphoma cancer after taking the drug injections, known as Dupixent®.
- If you have taken Dupixent® injections for as little as one month and receive a diagnosis of a form of Cutaneous T-Cell Lymphoma, our product litigation attorneys would like to discuss your possible claim for damages.
- Researchers recommend that doctors and physician assistants keep a close eye on their patients who are receive Dupixent® injections.
Drug Manufacturers of Dupixent Failed to Warn Doctors and Patients of the Risk of Skin Cancer
The Failure to Warn is a legal concept whereby the manufacturers and sellers of a product bear the responsibility of informing the public of any unseen risks associated with the use of their product and have failed in their responsibility.
Product Liability Lawyers You Can Count On
If you have received a skin cancer diagnosis of Cutaneous T-Cell Lymphoma, or if an existing slow-growing Cutaneous T-Cell Lymphoma condition worsens after receiving prescribed injections of Dupixent®, our product liability attorneys, Don and Charlie Ward, want to help you get the compensation you deserve.
What is Dupixent®
Dupixent® is the trade name for the human monoclonal antibody, a lab made protein prescribed for autoimmune Type 2 inflammatory conditions linked to certain types of eczema, asthma, and chronic rhinosinusitis nasal polyps.
How Does Dupixent Work
The active ingredient in Dupixent®, Dupilumab, blocks the signals of specific proteins (interleukin-4, and interleukin-13) on the patient’s immune or white blood cells. These proteins are the key drivers of Type 2 inflammation arising from allergic conditions such as eczema, chronic rhinosinusitis, and severe asthma.
Research Suggests a Link to Cutaneous T-Cell Lymphoma
Research studies have shown that Dupilumab, the active ingredient in Dupixent®, is linked to CTCL, a rare form of skin cancer, and may additionally intensify and worsen the effects of Dupixent® patients with pre-existing, slow-growing Cutaneous T-Cell Lymphoma.
Researchers suggest that Dupixent® patients and their health care providers carefully watch for changes to the skin. Untreated, the skin cancer, CTCL, may penetrate to internal organs.
Symptoms of Cutaneous T-Cell Lymphoma
If you are taking the Dupixent® injection for any of the conditions listed below, watch carefully for signs of patchy, dry, scaly, or discolored skin, rashes, tumors, swollen lymph nodes such as lumps in the neck, armpit or groin area, fever, chills, fatigue, unexpected weight loss, and/or loss of hair. These symptoms frequently link with CTCL.
Physicians May Prescribe Dupixent® For the Following Conditions
Doctors may prescribe Dupixent® for the following conditions:
- Chronic Rhinosinusitis (CRS) is the inflammation of nasal passages and sinuses occurring in 1%-5% of the population. It may result from infection, allergies, environmental irritants, or structural issues such as a deviated septum or nasal polyps. In rare cases, dental infection may spread to the sinuses. Symptoms vary but may include a stuffy nose, or facial pain and pressure. When Rhinosinusitis persists, it is treated as a chronic condition called Chronic Rhinosinusitis and may be treated with Dupilumab monoclonal antibodies, the active ingredients in Dupixent®.
- Eczema or Atopic Dermatitis (AD), an inflammatory, non-contagious condition, may cause dry, itchy, or red patches of skin which can ooze or become crusty. It is a result of an over-active immune response. Flare-ups of eczema may be managed with moisturizers, creams, or by blocking the receptors of the specific proteins as mentioned above. Globally, millions of people suffer from AD.
- Eosinophils Asthma (EA) – Asthma patients who present with a high count of white blood cells (eosinophils) leading to inflammation of various body parts and who are dependent upon oral corticosteroids, may indicate for subcutaneous injections of the human monoclonal antibody, Dupilumab in adults and in some children as young as six years old. In the United States alone, approximately 2.5 million people with severe asthma, in all probability, are apt to have Eosinophils Asthma or EA.
- Other inflammatory conditions may include Chronic Obstructive Pulmonary Disease (mucus-filled airways and damaged air sacs); Eosinophilic Esophagitis (swollen esophagus); Prurigo Nodularis (hard nodules that form due to chronic scratching); Chronic Spontaneous Urticaria, (commonly known as uncontrolled hives),and Bullous Pemphigoid (autoimmune skin disorder causing intense itching).
Product Liability Lawyers You Can Count On
If you have received a skin cancer diagnosis of Cutaneous T-Cell Lymphoma, or if a pre-existing slow-growing Cutaneous T-Cell Lymphoma condition worsens after receiving prescribed injections of Dupixent®, our partners, Don and Charlie Ward, want to speak with you because time may be running out to get you the compensation you deserve.
The Statute of Limitations
The state, via legislation, sets forth the amount of time a plaintiff has to file a civil claim against a negligent party or entity. The restriction is called the Statute of Limitations and can vary from state to state and even among defendant types. Attorneys need time to adequately prepare and mount a lawsuit against drug manufacturers. However, the statute restricts the amount of time to file suit after receiving a diagnosis.
If you wait too long to seek legal assistance, and in so doing exceed the statute of limitations, you may be forever barred from filing suit against the defendant for damages. That is why we encourage friends and clients to seek legal advice as soon as possible.
You Pay Nothing Until the Case Settles
Keep in mind if our firm takes your claim, you will pay nothing until your claim is settles.
Call the Dupixent® Litigation Lawyers Today
The clock is ticking! Call the Indiana Dupixent® litigation lawyers today for a no obligation, free consultation, at (317) 639-9501. We look forward to hearing from you.
Charles P. Ward
Ward & Ward Personal Injury Lawyers
PH: (317) 639-9501
Toll Free: (888) 639-9501
Disclaimer: The information provided on this website is for general informational purposes only and does not constitute legal advice. Accessing this information or contacting us does not form an attorney-client relationship. You should not rely on this information without consulting with a qualified attorney for advice tailored to your specific situation.
January 15, 2026
Learn more about Product Liability Claims
Free Consultation
Talk to an experienced injury attorney
Contact Our Office Today
728 S Meridian St, Indianapolis, IN 46225
